Abstract 2566: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
James Kelly(Redx Pharma (United Kingdom)), Caroline Phillips(Redx Pharma (United Kingdom)), Simon A. Woodcock(Bio-Medical Science (South Korea)), Inder Bhamra(Redx Pharma (United Kingdom)), Jane Robertson(Cancer Research UK), Richard Armer(Redx Pharma (United Kingdom)), Cliff Jones(Redx Pharma (United Kingdom))
Cited by 2
Related Papers
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233